Abbott Reports New (FLASH-UK) Trial Results of FreeStyle Libre 2 System for Type 1 Diabetes and Sub-Optimal Glycemic Control
- The (FLASH-UK) trial evaluates the FreeStyle Libre 2 system vs self-monitoring of blood glucose (SMBG) in a ratio (1:1) in 156 patients aged ≥16yrs. with T1D. The trial was led by a team at The University of Manchester together with investigators from 8 centers in the UK & funded by Diabetes UK
- The results showed reductions in HbA1c levels @24wks., improvements in patients-reported QoL outcomes incl. overall satisfaction & reduction in burden associated with glucose monitoring. The results were published in the NEJM
- Patients who used FreeStyle Libre 2 system achieved a reduction in HbA1c levels by an avg. of 0.8% (8.7% to 7.9%) after 6mos. over 0.2% (8.5% to 8.3%) in SMBG, avg. HbA1c level was 0.3% lower @12wks. & 0.5% lower @24wks. than those using SMBG
Ref: PRNewswire | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].